{
  "abstract": "We aimed to describe the response of chronic ocular graft versus host disease (oGVHD) to systemic belumosudil. A total of seven patients were included. Five patients underwent allogeneic stem cell transplant and two patients received allogeneic peripheral blood stem cell transplant. After starting belumodusil treatment (average treatment duration 22.3 months), three patients had reduced corneal fluorescein staining. Resolution of filamentary keratopathy was noted in four patients. Ocular discomfort score improved in four patients. Visual acuity remained stable for all patients. Our case series showed that belumosudil use in oGvHD may offer improvement or stabilisation and should be investigated further.",
  "authors": [
    {
      "affiliations": [
        "University of Maryland School of Medicine, Baltimore, Maryland, USA"
      ],
      "name": "Charlyn Gomez"
    },
    {
      "affiliations": [
        "University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA"
      ],
      "name": "Fernando Martinez Guasch"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"
      ],
      "name": "Vishal Jhanji"
    },
    {
      "affiliations": [
        "University of Maryland School of Medicine, Baltimore, Maryland, USA"
      ],
      "name": "Sarah Brem Sunshine"
    }
  ],
  "title": "Systemic Rho-kinase inhibitor belumosudil for treatment of ocular graft versus host disease",
  "uid": "6266f446-27ac-51f7-a1cd-73f30ecf8ff5"
}